Stories about Averitas Pharma

Subscribe to Averitas Pharma

18.12.2019 – 14:07

Grünenthal Group
Averitas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ...

more
14.11.2018 – 08:45

Grünenthal Group
Grünenthal acquires Averitas Pharma and establishes commercial footprint in the US

Aachen, Germany / Morristown, New Jersey, USA (ots) - Grünenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza® (8 % capsaicin) for Grünenthal in the US. Grünenthal had only recently acquired the ...

more

1